Gilead Extends Tender Offer to Acquire Arcellx Gilead Sciences, Inc. today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus one contractual contingent value right, which represents the right to receive one...

#GILD Gilead Extends Tender Offer to Acquire Arcellx

www.stocktitan.net/news/GILD/gilead-extends...

Stock index futures swing as traders keep an eye on Iran conflict (SPX:) U.S. stock futures rise as traders track U.S.-Israel-Iran tensions, Treasury yields and key data ahead.

Stock index futures swing as traders keep an eye on Iran conflict

#spx #indu #us100:ind #ato #gild #bax #apo #ctva #us10y #us2y #us30y

Origin | Interest | Match

A single-cycle autoimmune drug candidate sits at center of Gilead's $1.68B deal OM336 showed efficacy after one treatment cycle in early studies. The deal expands Gilead's autoimmune pipeline; key studies are due in 2027.

#GILD Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

www.stocktitan.net/news/GILD/gilead-science...

Had a friend recommend this book to me. What I didn’t expect was the “OH…okay…so we’re just starting out like this? Got it.” 😂 #Books #Gild #RavenKennedy

Article image

Gilead Sciences (GILD) gets upgrades from key analysts. The stock could see a strong upturn if growth estimates hold. Watch for upcoming revenue data. #GILD #Stocks #Investing #StressStreet

Article image

Gilead Sciences (GILD) riceve upgrade da analisti chiave. Il titolo potrebbe registrare un forte rialzo se le stime di crescita si confermano. Attenzione ai prossimi dati sui ricavi. #GILD #Borsa #Investimenti #TachicardiaTrading

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia Gilead Foundation (Nasdaq: GILD) announced a $12 million grant program funding 33 community organizations across 14 states and the District of Columbia through a two-year Community Health Worker (CHW) HIV prevention initiative. The effort expands CHW-led prevention, training, screening, navigation, and culturally aligned outreach prioritizing communities most impacted by HIV.The grants support integrated screening for HIV, STIs, mental health and substance use, peer navigation, promotores models, pharmacy training, and youth-focused programming to strengthen local prevention networks and reduce stigma.

#GILD Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

www.stocktitan.net/news/GILD/gilead-foundat...

Josh Gottheimer - Integrity Index View Josh Gottheimer's political integrity grade, campaign financing, and conflicts of interest.

Rep. Josh Gottheimer (D-NJ) disclosed 1 trade:
Traded: Jan 27 | Disclosed: Feb 26

Bought: $GILD ($1K-$15K)

https://integrityindex.us/candidate/josh-gottheimer

💥 #ACLX = +80% #GILD = -1%

Gilead to buy cancer drug developer Arcellx for up to $7.8bn

after earnings

#GILD Gilead = -2%
#HOOD Robinhood = -8%
#LYFT Lyft = -17%
#F Ford = +1%

Gilead Expands Oncology Dealmaking With $300M OncoNano Drug Delivery Collaboration Gilead Sciences (NASDAQ: GILD) has entered into an expanded partnership with OncoNano Medicine, committing up to $300 million to accelerate development of OncoN

Gilead Sciences (NASDAQ: #GILD) is boosting its oncology push with a new collaboration using OncoNano’s ON-BOARD drug delivery platform, a deal that could pay OncoNano up to $300 million in milestones and royalties.
prismmarketview.com/gilead-expan...

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate OncoNano Medicine announced a research collaboration with Gilead (Nasdaq: GILD) to evaluate OncoNano’s ON-BOARD™ encapsulation technology with a Gilead drug candidate on January 6, 2026.Terms include an upfront payment, near-term preclinical milestones, development/regulatory/commercial milestones, and royalties on net sales. Gilead may expand the collaboration by nominating another target; aggregate payments to OncoNano could reach $300 million including upfront and milestone payments, plus royalties. The work will assess stability, selectivity, and efficacy of the encapsulated asset and test ON-BOARD’s tumor-localized delivery claims.

#GILD OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate

www.stocktitan.net/news/GILD/onco-nano-medi...

U.S. stocks struggle as tech-led sell-off continues into the year's last days (DJI:) Get the latest stock market update, premarket gainers & losers, and key insights ahead of the FOMC minutes.

Wall Street stretches tech-led sell-off into the last days of the year

#dji #sp500 #comp:ind #wdc #gild #shop #pltr #xptusd:cur #hg1:com #xagusd:cur #xauusd:cur

Origin | Interest | Match

U.S. stocks struggle as tech-led sell-off continues into the year's last days (DJI:) Get the latest stock market update, premarket gainers & losers, and key insights ahead of the FOMC minutes.

U.S. stocks struggle as tech-led sell-off continues into the year's last days

#dji #sp500 #comp:ind #wdc #gild #shop #pltr #xagusd:cur #app #us10y #us2y

Origin | Interest | Match

Kiteが発表した次世代CAR T細胞療法の有望な結果 Kiteは次世代バイシストロニックCAR T細胞療法の新データを発表。再発大細胞型B細胞リンパ腫に希望の光が差し込む！

Kiteが発表した次世代CAR T細胞療法の有望な結果 #GILD #Kite #CAR_T細胞

Kiteは次世代バイシストロニックCAR T細胞療法の新データを発表。再発大細胞型B細胞リンパ腫に希望の光が差し込む！

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans Gilead Sciences, Inc. today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’ s long-standing commitment to U.S.- based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that...

#GILD Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

www.stocktitan.net/news/GILD/gilead-and-u-s...

#GILD Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

www.stocktitan.net/news/GILD/gilead-s-inves...

Breaking News: ( NASDAQ: #GILD ) Yescarta Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma Kite (Nasdaq: GILD) and Arcellx reported updated pivotal iMMagine-1 Phase 2 data for investigational anitocabtagene autoleucel (anito-cel) at ASH 2025 with a cutoff of Oct 7, 2025 and median follow-up of 15.9 months.Key results: ORR 96%, sCR/CR 74%, MRD negativity 95% (≤10-5), 12/18/24-month PFS of 82.1%/67.4%/61.7%, and 12/18/24-month OS of 94%/88%/83%. Safety was described as predictable and manageable: CRS 86% (mostly Grade 1), ICANS 8% (one Grade 3), and no delayed non-ICANS neurotoxicities observed to date.

#GILD Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

www.stocktitan.net/news/GILD/kite-announces...

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 Gilead (Nasdaq: GILD) presented Phase 1 data at ASH 2025 showing encouraging efficacy and tolerability for two investigational bicistronic CAR T therapies, KITE-753 and KITE-363, targeting CD19 and CD20 with dual co-stimulation.Key data: in KITE-753 dose level 3 (0.2×106 CAR T/kg) 11 of 14 CAR‑naïve patients (79%) had complete responses at median follow-up 2.9–4.0 months; across KITE-753 dose levels 14 of 20 CAR‑naïve patients achieved complete responses. KITE-363 showed durable remissions with median follow-up 17.5 months and >70% of evaluable complete responders at 12 months remaining in remission. No dose‑limiting toxicities reported.

#GILD Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

www.stocktitan.net/news/GILD/kite-s-next-ge...

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa Gilead (Nasdaq: GILD) announced first shipments of lenacapavir, a twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), to Eswatini and Zambia on Nov 18, 2025. The deliveries follow U.S., EU, South Africa and Zambia approvals and come five months after U.S. FDA approval. Gilead will supply lenacapavir at no profit for up to two million people until generics scale, and has royalty-free licences with six generic manufacturers covering 120 countries. Regulatory submissions for PrEP are planned in 18 additional countries by year-end 2025; further country arrivals, including South Africa, are expected in early 2026.

#GILD Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

www.stocktitan.net/news/GILD/gilead-joins-p...

#AMGN #GILD #4f46963d-308f-4b88-80dd-4b1306cf5e3a #investing #Health #Care

Origin | Interest | Match

#GILD Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

www.stocktitan.net/news/GILD/gilead-s-inves...

Gilead Provides Update on Phase 3 ASCENT-07 Study Gilead (NASDAQ: GILD) announced that the Phase 3 ASCENT-07 study of Trodelvy (sacituzumab govitecan-hziy) versus physician’s choice chemotherapy in first treatment post-endocrine therapy for HR+/HER2-negative metastatic breast cancer did not meet its primary endpoint of blinded independent central review-assessed progression-free survival (PFS) per RECIST v1.1 on Nov 7, 2025. The study enrolled 654 patients randomized 2:1 and will continue to follow patients for overall survival (OS), a key secondary endpoint that was not mature at the primary analysis but showed an early trend favoring Trodelvy. Safety was consistent with prior Trodelvy studies and no new safety signals were identified.Trodelvy remains approved for certain pre-treated HR+/HER2-negative and later-line TNBC indications and is being further evaluated in ongoing Phase 3 trials.

#GILD Gilead Provides Update on Phase 3 ASCENT-07 Study

www.stocktitan.net/news/GILD/gilead-provide...

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 Gilead Sciences, Inc. and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology Annual Meeting and Exposition. These data showcase Kite’ s continued progress in transforming blood cancer care and expanding the reach and impact of CAR T-cell therapy. This press release features...

#GILD Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

www.stocktitan.net/news/GILD/gilead-and-kit...

Gilead Sciences Announces Third Quarter 2025 Financial Results Total third quarter 2025 revenues increased 3% to $7.8 billion compared to the same period in 2024, broken down as follows: Total third quarter 2025 product sales decreased 2% to $7.3 billion compared to the same period in 2024, primarily driven by lower Veklury ® and Cell Therapy sales, partially offset by higher HIV and Livdelzi ® sales. Total third quarter...

#GILD Gilead Sciences Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/GILD/gilead-science...

These books right here from book 1 chapter 1 I was expecting smutty king Midas weird kinky romp but it’s partially that and so much more I’m halfway through book 2 and I’m hooked and so pleasantly surprised #gild #platedprisoner

News; ( NASDAQ: #GILD ) Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025